Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 2, 2010, Pages 501-518

  Papke, Roger L ^a   Wecker, Lynn ^b   Stitzel, Jerry A ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BUNGAROTOXIN RECEPTOR; CHOLINERGIC RECEPTOR; CYTISINE; DECAMETHONIUM; DIHYDRO BETA ERYTHROIDINE; HEXAMETHONIUM; MECAMYLAMINE; MUSCLE NICOTINIC ACETYLCHOLINE RECEPTOR; NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR; NICOTINIC ALPHA3BETA4 RECEPTOR; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL CELL; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; MOUSE; MUSCLE; MUSCLE CONTRACTION; NERVE CELL; NEUROMUSCULAR FUNCTION; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECIES; STOICHIOMETRY; XENOPUS;

ACETYLCHOLINE; ALKALOIDS; ANIMALS; AZOCINES; BENZAZEPINES; DECAMETHONIUM COMPOUNDS; DIHYDRO-BETA-ERYTHROIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; GENE EXPRESSION; HEXAMETHONIUM; HUMANS; MECAMYLAMINE; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; NICOTINIC ANTAGONISTS; OOCYTES; QUINOLIZINES; QUINOXALINES; RATS; RECEPTORS, NICOTINIC; XENOPUS LAEVIS;

EID: 77951032908     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.164566     Document Type: Article

References (40)

1. Andreasen JT, Olsen GM, Wiborg O, and Redrobe JP (2008) Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. J Psychopharmacol 23:797-804.
2. Azam L, Dowell C, Watkins M, Stitzel JA, Olivera BM, and McIntosh JM (2005) α-Conotoxin BuIA, a novel peptide from Conus bullatus, distinguishes among neuronal nicotinic acetylcholine receptors. J Biol Chem 280:80-87. (Pubitemid 40164967)
3. Ball C and Westhorpe R (2005) Muscle relaxants: decamethonium. Anaesth Intensive Care 33:709.
4. Champtiaux N and Changeux JP (2004) Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system. Prog Brain Res 145:235-251. (Pubitemid 37442947)
5. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, et al. (2005) Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474-3477. (Pubitemid 40664098)
6. de Jonge WJ and Ulloa L (2007) The α7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 151:915-929. (Pubitemid 47195518)
7. Dobelis P, Marks MJ, Whiteaker P, Balogh SA, Collins AC, and Stitzel JA (2002) A polymorphism in the mouse neuronal α4 nicotinic receptor subunit results in an alteration in receptor function. Mol Pharmacol 62:334-342. (Pubitemid 34804114)
8. Grady SR, Salminen O, McIntosh JM, Marks MJ, and Collins AC (2009) Mouse striatal dopamine nerve terminals express α4α5β2 and two stoichiometric forms of α4β*-nicotinic acetylcholine receptors. J Mol Neurosci 40:91-95.
9. Hussy N, Ballivet M, and Bertrand D (1994) Agonist and antagonist effects of nicotine on chick neuronal nicotinic receptors are defined by α and β subunits. J Neurophys 72:1317-1326. (Pubitemid 24294848)
10. Jonsson M, Gurley D, Dabrowski M, Larsson O, Johnson EC, and Eriksson LI (2006) Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade. Anesthesiology 105:521-533. (Pubitemid 44310435)
11. Kim H, Flanagin BA, Qin C, Macdonald RL, and Stitzel JA (2003) The mouse Chrna4 A529T polymorphism alters the ratio of high- to low-affinity α4β2 nAChRs. Neuropharmacology 45:345-354. (Pubitemid 36836131)
12. Kuryatov A, Onksen J, and Lindstrom J (2008) Roles of accessory subunits in α4β2* nicotinic receptors. Mol Pharmacol 74:132-143. (Pubitemid 351872165)
13. Liu Y and Dilger JP (1993) Decamethonium is a partial agonist at the nicotinic acetylcholine receptor. Synapse 13:57-62. (Pubitemid 23020142)
14. Marubio LM and Changeux J (2000) Nicotinic acetylcholine receptor knockout mice as animal models for studying receptor function. Eur J Pharmacol 393:113-121.
15. Mihalak KB, Carroll FI, and Luetje CW (2006) Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 70:801-805. (Pubitemid 44268437)
16. Millar NS and Gotti C (2009) Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 56:237-246.
17. Mineur YS, Eibl C, Young G, Kochevar C, Papke RL, Gundisch D, and Picciotto MR (2009) Cytisine-based nicotinic partial agonists as novel antidepressant compounds. J Pharmacol Exp Ther 329:377-386.
18. Moroni M, Zwart R, Sher E, Cassels BK, and Bermudez I (2006) α4β2 Nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharmacol 70:755-768. (Pubitemid 44092336)
19. Neher E and Steinbach JH (1978) Local anaesthetics transiently block current through single acetylcholine receptor channels. J Physiol 277:135-176. (Pubitemid 8379610)
20. Nelson ME, Kuryatov A, Choi CH, Zhou Y, and Lindstrom J (2003) Alternate stoichiometries of α4β2 nicotinic acetylcholine receptors. Mol Pharmacol 63:332-341. (Pubitemid 36158368)
21. Papke RL (2006) Estimation of both the potency and efficacy of α7 nAChR agonists from single-concentration responses. Life Sci 78:2812-2819.
22. Papke RL (2009) Tricks of perspective: insights and limitations to the study of macroscopic currents for the analysis of nAChR activation and desensitization. Mol Neurosci 40:77-86.
23. Papke RL, Buhr JD, Francis MM, Choi KI, Thinschmidt JS, and Horenstein NA (2005) The effects of subunit composition on the inhibition of nicotinic receptors by the amphipathic blocker 2,2,6,6-tetramethylpiperidin-4-yl heptanoate. Mol Pharmacol 67:1977-1990.
24. Papke RL, Dwoskin LP, Crooks PA, Zheng G, Zhang Z, McIntosh JM, and Stokes C (2008) Extending the analysis of nicotinic receptor antagonists with the study of α6 nicotinic receptor subunit chimeras. Neuropharmacology 54:1189-1200.
25. Papke RL and Heinemann SF (1994) The partial agonist properties of cytisine on neuronal nicotinic receptors containing the β2 subunit. Mol Pharm 45:142-149.
26. Papke RL and Papke JKP (2002) Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis. Br J Pharmacol 137:49-61.
27. Paton WDA and Perry WLM (1953) The relationship between depolarization and block in the cat's superior cervical ganglion. J Physiol 119:43-57.
28. Paton WDA and Zaimis EJ (1949) The pharmacological actions of polymethylene bis-trimethylammonium salts. Br J Pharmacol 4:381-400.
29. Patrick J, Boulter J, Goldman D, Gardner P, and Heinemann S (1987) Molecular biology of nicotinic acetylcholine receptors. Ann NY Acad Sci 505:194-207.
30. Picciotto M, Zoli M, Rimondini R, Lena C, Marubio L, Pich E, Fuxe K, and Changeux J (1998) Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-177. (Pubitemid 28092475)
31. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, et al. (2007) Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994. (Pubitemid 46227486)
32. Rollema H, Guanowsky V, Mineur YS, Shrikhande A, Coe JW, Seymour PA, and Picciotto MR (2009) Varenicline has antidepressant-like activity in the forced-swim test and augments sertraline's effect. Eur J Pharmacol 605:114-116.
33. Stitzel JA, Dobelis P, Jimenez M, and Collins AC (2001) Long sleep and short sleep mice differ in nicotine-stimulated 86Rb+ efflux and α4 nicotinic receptor subunit cDNA sequence. Pharmacogenetics 11:331-339.
34. Stitzel JA, Farnham DA, and Collins AC (1996) Linkage of strain-specific nicotinic receptor α7 subunit restriction fragment-length polymorphisms with levels of α-bungarotoxin binding in brain. Brain Res Mol Brain Res 43:30-40.
35. 2+ permeability of the (α4)3(β2)2 stoichiometry greatly exceeds that of (α4)2(β2)3 human acetylcholine receptors. Mol Pharmacol 71:769-776.
36. Wang N, Orr-Urtreger A, Chapman J, Ergun Y, Rabinowitz R, and Korczyn AD (2005) Hidden function of neuronal nicotinic acetylcholine receptor β2 subunits in ganglionic transmission: comparison to α5 and β4 subunits. J Neurol Sci 228:167-177. (Pubitemid 40202963)
37. Wang N, Orr-Urtreger A, Chapman J, Rabinowitz R, Nachman R, and Korczyn AD (2002) Autonomic function in mice lacking α5 neuronal nicotinic acetylcholine receptor subunit. J Physiol 542:347-354. (Pubitemid 35190298)
38. Yu CR and Role LW (1998) Functional contribution of the α5 subunit to neuronal nicotinic channels expressed by chick sympathetic ganglion neurones. J Physiol 509:667-681. (Pubitemid 28306132)
39. Zhou Y, Nelson ME, Kuryatov A, Choi C, Cooper J, and Lindstrom J (2003) Human α4β2 acetylcholine receptors formed from linked subunits. J Neurosci 23:9004-9015. (Pubitemid 37243801)
40. Zwart R, Broad LM, Xi Q, Lee M, Moroni M, Bermudez I, and Sher E (2006) 5-I A-85380 and TC-2559 differentially activate heterologously expressed α4β2 nicotinic receptors. Eur J Pharmacol 539:10-17. (Pubitemid 43796324)